Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Paradox Immunotherapeutics

Request full access

Reshaping the future of protein misfolding diseases

Toronto, CanadaFounded 2019Biotech & Life Sciences

About Paradox Immunotherapeutics

Paradox Immunotherapeutics is a preclinical-stage biotechnology company founded in 2019, operating from Toronto, Canada. The firm is focused on creating monoclonal antibody (mAb) treatments for protein misfolding diseases, such as various forms of amyloidosis. These conditions occur when proteins fail to form their correct shape, leading to the creation of toxic deposits that disrupt tissue and organ function. The company's business model centers on the discovery and development of these specialized antibody therapies, which are designed to selectively target and clear only the harmful misfolded proteins, leaving healthy proteins unharmed.

The company was co-founded by Dr. Natalie Galant, who serves as CEO, and Dr. Yulong Sun, the Chief Scientific Officer. Both founders earned their PhDs in medical biophysics from the University of Toronto. Dr. Galant's doctoral research contributed to the development of a monoclonal antibody for cardiac amyloidosis, which is now in FDA clinical trials after being part of a $1.2 billion acquisition deal in 2021. This background provides the foundational science for Paradox's proprietary drug discovery platform. The platform utilizes a structural-based algorithm to predict specific regions on a protein that emerge during misfolding, enabling the creation of antibodies that precisely target these deviant forms.

Paradox Immunotherapeutics serves patients with rare and life-threatening diseases that currently have ineffective treatment options. The company's pipeline includes candidates like LX-96 for immunoglobulin light chain (AL) amyloidosis, KX-99 for leukocyte chemotactic factor 2 (LECT2) amyloidosis which affects the kidneys, and NX-86 for neurodegenerative diseases. In February 2025, the company secured $10 million in financing led by SymBiosis Capital Management to advance its therapeutic pipeline toward clinical milestones. This funding followed numerous recognitions, including being a finalist at J.P. Morgan's Life Sciences Innovation Summit and a winner at the BIO Emerging Company Start-Up Stadium.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
1
Dealroom signal
77.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Disease, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Feb 2025 $10M $40M SymBiosis ↗
SPINOUTOther financing Jan 2019 $0 — University of Toronto —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Paradox Immunotherapeutics website traffic

Latest recorded traffic for Paradox Immunotherapeutics is 910 monthly website visits, up 313.6% over the last three months. Paradox Immunotherapeutics's team grew 33.3% over the past year.

Latest monthly visits910 3-month web change+313.6% 1-year team growth+33.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Xanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing Lower Merion Township, United States Operational 9 $11M $44M
AviadoBioPrecision gene therapies for neurodegenerative disorders London, United Kingdom Operational
Teitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases Aarhus, Denmark Operational
Tay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise Dundee, United Kingdom Operational
Rectify PharmaceuticalsBreakthrough ABC transporter platform enabling rapid discovery of small molecule therapies for liver, biliary, eye, CNS, and cardiometabolic diseases Cambridge, United States Operational
Stratus TherapeuticsDeveloping off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases Natick, United States Operational
Lexeo TherapeuticsRevolutionizes human health therapeutics by applying the science of gene therapy to treat and cure some of the world’s most devastating genetic and acquired diseases New York City, United States Operational
TruSpin Nanomaterial Innovation, Inc.Mass-produces high aspect ratio nanofibers across a wide range of inorganic, organic, and polymer compositions Birmingham, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Paradox Immunotherapeutics in the Toronto ecosystem

Live from Dealroom

The Paradox Immunotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • SymBiosis

Other known investors1 additional known investor

  • University of Toronto
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇦 Canada80%
🇺🇸 United States20%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Paradox Immunotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Paradox Immunotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.